title: [Clinical studies of terodiline hydrochloride and clenbuterol hydrochloride for urinary frequency and incontinence].
abstract: The clinical effectiveness and safety of terodiline hydrochloride and clenbuterol hydrochloride were studied on 51 patients with neurogenic bladder, stress incontinence, unstable bladder and others, the chief complaints of which were urinary frequency or urinary incontinence. Overall improvement was graded as marked in 6 patients (11.8%), moderate in 20 patients (39.2%), slight in 11 patients (21.6%), unchanged in 13 patients (25.5%) and aggravated in one. The patients impression was "good" or better in 56.9%. There were a total of 13 cases (25.5%) of adverse reactions, namely, 7 cases of finger tremor, 3 cases of dry mouth and others. These reactions disappeared rapidly after the discontinuance of drug administration. The clinical efficacy in the treatment of subjective symptoms was 71.4% for urinary incontinence, 56.4% for diurnal pollakisuria. The examination of lower urethral functions demonstrated a significant (p less than 0.01) increase in bladder capacity at first desire and maximum desire to void. However, we found no significant increase in urethral clossure pressure. The findings of this study suggest that terodiline hydrochloride and clenbuterol hydrochloride are very useful for the treatment of urinary frequency and incontinence.
authors.affiliation: Department of Urology, Kanazawa National Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Katsumi
authors.forename: K
authors.initials: K
authors.lastname: Murayama
authors.forename: E
authors.initials: E
authors.lastname: Tajika
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: K
authors.initials: K
authors.lastname: Kawaguchi
mesh_terms: D000368:Aged; D002082:Butylamines / Q000008:administration & dosage*; D002976:Clenbuterol / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008365:Manometry; D011141:Polyuria / Q000188:drug therapy* / Q000503:physiopathology; D014521:Urethra / Q000503:physiopathology; D001743:Urinary Bladder / Q000503:physiopathology; D001750:Urinary Bladder, Neurogenic / Q000150:complications; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D002082:Butylamines; C010637:terodiline; D002976:Clenbuterol